What is Closed Loop Medicine?
Closed Loop Medicine operates at the intersection of pharmacology and digital technology, positioning itself as a leader in the development of personalized care regimens. By integrating pharmaceutical treatments with digital health platforms and medical devices, the company creates a closed-loop system that monitors patient progress and adjusts therapy in real-time. Currently, the firm is prioritizing the treatment of sleep disorders and hypertension, leveraging its deep-tech foundation to improve patient adherence and therapeutic efficacy. Their market position is defined by a commitment to evidence-based medicine, aiming to reduce the burden on global health systems by providing more precise, outcome-oriented care solutions.
How much funding has Closed Loop Medicine raised?
Closed Loop Medicine has raised a total of $21.9M across 3 funding rounds:
Other Financing Round
$3.9M
Grant
$319K
Unspecified
$17.6M
Other Financing Round (2020): $3.9M with participation from Cambridge Angels, BGF, Longwall Ventures, Martlet, and IQ Capital
Grant (2020): $319K, investors not publicly disclosed
Unspecified (2021): $17.6M, investors not publicly disclosed
Key Investors in Closed Loop Medicine
Cambridge Angels
A prominent UK business angel network consisting of exited entrepreneurs who provide smart capital and mentorship to early-stage healthcare and technology ventures.
BGF
An influential independent investment firm that supports the growth of small and mid-sized businesses across various sectors in the United Kingdom.
Longwall Ventures
A venture firm specializing in early-stage deep-tech businesses that leverage scientific R&D to solve complex global challenges.
What's next for Closed Loop Medicine?
With the recent strategic investment of $17.6M, Closed Loop Medicine is well-positioned to accelerate its clinical development pipeline and expand its therapeutic focus beyond its current core areas. The company is expected to leverage this capital to scale its digital infrastructure, enhance its proprietary algorithms, and pursue regulatory milestones necessary for broader market adoption. As the firm transitions into a more mature enterprise phase, the focus will likely shift toward commercialization strategies and the integration of its platform into existing healthcare ecosystems. By continuing to bridge the gap between traditional drug development and modern digital health, Closed Loop Medicine is poised to set new standards for personalized medicine on a global scale.
See full Closed Loop Medicine company page
